430 related articles for article (PubMed ID: 32079420)
41. Functional characteristics of the novel, human-derived recombinant FVIII protein product, human-cl rhFVIII.
Sandberg H; Kannicht C; Stenlund P; Dadaian M; Oswaldsson U; Cordula C; Walter O
Thromb Res; 2012 Nov; 130(5):808-17. PubMed ID: 23010293
[TBL] [Abstract][Full Text] [Related]
42. Mechanisms of vascular permeability and remodeling associated with hemarthrosis in factor VIII-deficient mice.
Cooke EJ; Wyseure T; Zhou JY; Gopal S; Nasamran CA; Fisch KM; Manon-Jensen T; Karsdal MA; Mosnier LO; von Drygalski A
J Thromb Haemost; 2019 Nov; 17(11):1815-1826. PubMed ID: 31301687
[TBL] [Abstract][Full Text] [Related]
43. Factor VIII inhibitor development in Egyptian hemophilia patients: does intron 22 inversion mutation play a role?
Sherief LM; Gaber OA; Youssef HM; Sherbiny HS; Mokhtar WA; Ali AAA; Kamal NM; Abdel Maksoud YH
Ital J Pediatr; 2020 Sep; 46(1):129. PubMed ID: 32928254
[TBL] [Abstract][Full Text] [Related]
44. Spotlight on the human factor: building a foundation for the future of haemophilia A management: report from a symposium on human recombinant FVIII at the World Federation of Hemophilia World Congress, Melbourne, Australia on 12 May 2014.
Kessler C; Oldenburg J; Ettingshausen CE; Tiede A; Khair K; Négrier C; Klamroth R
Haemophilia; 2015 Jan; 21 Suppl 1():1-12. PubMed ID: 25472812
[TBL] [Abstract][Full Text] [Related]
45. Intra-articular injection of mesenchymal stem cells expressing coagulation factor ameliorates hemophilic arthropathy in factor VIII-deficient mice.
Kashiwakura Y; Ohmori T; Mimuro J; Yasumoto A; Ishiwata A; Sakata A; Madoiwa S; Inoue M; Hasegawa M; Ozawa K; Sakata Y
J Thromb Haemost; 2012 Sep; 10(9):1802-13. PubMed ID: 22784361
[TBL] [Abstract][Full Text] [Related]
46. Factor VIII associated with lipidic nanoparticles retains efficacy in the presence of anti-factor VIII antibodies in hemophilia A mice.
Shetty KA; Kosloski MP; Mager DE; Balu-Iyer SV
Biopharm Drug Dispos; 2016 Oct; 37(7):409-420. PubMed ID: 27418232
[TBL] [Abstract][Full Text] [Related]
47. Gene therapy for the hemophilias.
VandenDriessche T; Collen D; Chuah MK
J Thromb Haemost; 2003 Jul; 1(7):1550-8. PubMed ID: 12871290
[TBL] [Abstract][Full Text] [Related]
48. Phenotypic correction of a mouse model of hemophilia A using AAV2 vectors encoding the heavy and light chains of FVIII.
Scallan CD; Liu T; Parker AE; Patarroyo-White SL; Chen H; Jiang H; Vargas J; Nagy D; Powell SK; Wright JF; Sarkar R; Kazazian HH; McClelland A; Couto LB
Blood; 2003 Dec; 102(12):3919-26. PubMed ID: 12893764
[TBL] [Abstract][Full Text] [Related]
49. Ultra-sensitive AAV capsid detection by immunocapture-based qPCR following factor VIII gene transfer.
Sandza K; Clark A; Koziol E; Akeefe H; Yang F; Holcomb J; Patton K; Hammon K; Mitchell N; Wong WY; Zoog SJ; Kim B; Henshaw J; Vettermann C
Gene Ther; 2022 Feb; 29(1-2):94-105. PubMed ID: 34421119
[TBL] [Abstract][Full Text] [Related]
50. Maladaptive lymphangiogenesis is associated with synovial iron accumulation and delayed clearance in factor VIII-deficient mice after induced hemarthrosis.
Cooke EJ; Joseph BC; Nasamran CA; Fisch KM; von Drygalski A
J Thromb Haemost; 2023 Sep; 21(9):2390-2404. PubMed ID: 37116753
[TBL] [Abstract][Full Text] [Related]
51. CD32 inhibition and high dose of rhFVIII suppress murine FVIII-specific recall response by distinct mechanisms in vitro.
Vollack N; Friese J; Bergmann S; Tiede A; Werwitzke S
Thromb Haemost; 2017 Aug; 117(9):1679-1687. PubMed ID: 28492697
[TBL] [Abstract][Full Text] [Related]
52. A multicenter study of recombinant factor VIII (recombinate): safety, efficacy, and inhibitor risk in previously untreated patients with hemophilia A. The Recombinate Study Group.
Bray GL; Gomperts ED; Courter S; Gruppo R; Gordon EM; Manco-Johnson M; Shapiro A; Scheibel E; White G; Lee M
Blood; 1994 May; 83(9):2428-35. PubMed ID: 8167332
[TBL] [Abstract][Full Text] [Related]
53. Factor VIII inhibitors: von Willebrand factor makes a difference in vitro and in vivo.
Shi Q; Kuether EL; Schroeder JA; Perry CL; Fahs SA; Cox Gill J; Montgomery RR
J Thromb Haemost; 2012 Nov; 10(11):2328-37. PubMed ID: 22908929
[TBL] [Abstract][Full Text] [Related]
54. Characteristics of Minimally Oversized Adeno-Associated Virus Vectors Encoding Human Factor VIII Generated Using Producer Cell Lines and Triple Transfection.
Nambiar B; Cornell Sookdeo C; Berthelette P; Jackson R; Piraino S; Burnham B; Nass S; Souza D; O'Riordan CR; Vincent KA; Cheng SH; Armentano D; Kyostio-Moore S
Hum Gene Ther Methods; 2017 Feb; 28(1):23-38. PubMed ID: 28166648
[TBL] [Abstract][Full Text] [Related]
55. Antibodies to factor VIII in plasma of patients with hemophilia A and normal subjects.
Batlle J; Gómez E; Rendal E; Torea J; Lourés E; Couselo M; Vila P; Sedano C; Tusell X; Magallón M; Quintana M; González-Boullosa R; López-Fernández MF
Ann Hematol; 1996 May; 72(5):321-6. PubMed ID: 8645745
[TBL] [Abstract][Full Text] [Related]
56. Ex vivo gene therapy for hemophilia A that enhances safe delivery and sustained in vivo factor VIII expression from lentivirally engineered endothelial progenitors.
Matsui H; Shibata M; Brown B; Labelle A; Hegadorn C; Andrews C; Hebbel RP; Galipeau J; Hough C; Lillicrap D
Stem Cells; 2007 Oct; 25(10):2660-9. PubMed ID: 17615271
[TBL] [Abstract][Full Text] [Related]
57. Therapeutic factor VIII levels and negligible toxicity in mouse and dog models of hemophilia A following gene therapy with high-capacity adenoviral vectors.
Chuah MK; Schiedner G; Thorrez L; Brown B; Johnston M; Gillijns V; Hertel S; Van Rooijen N; Lillicrap D; Collen D; VandenDriessche T; Kochanek S
Blood; 2003 Mar; 101(5):1734-43. PubMed ID: 12406898
[TBL] [Abstract][Full Text] [Related]
58. Successful immune tolerance induction with high-dose coagulation factor VIII and intravenous immunoglobulins in a patient with congenital hemophilia and high-titer inhibitor of coagulation factor VIII despite unfavorable prognosis for the therapy.
Kubisz P; Plamenová I; Hollý P; Stasko J
Med Sci Monit; 2009 Jun; 15(6):CS105-11. PubMed ID: 19488019
[TBL] [Abstract][Full Text] [Related]
59. Lentivirus-mediated platelet gene therapy of murine hemophilia A with pre-existing anti-factor VIII immunity.
Kuether EL; Schroeder JA; Fahs SA; Cooley BC; Chen Y; Montgomery RR; Wilcox DA; Shi Q
J Thromb Haemost; 2012 Aug; 10(8):1570-80. PubMed ID: 22632092
[TBL] [Abstract][Full Text] [Related]
60. Induction of tolerance to human factor VIII in mice.
Chao H; Walsh CE
Blood; 2001 May; 97(10):3311-2. PubMed ID: 11342466
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
